The Benefits Outweigh the Risks: Unpacking the Recent ODAC Decisions in Myeloma
May 13th 2024Following the consensus that the risk-benefit assessments for the proposed indications for cilta-cel and ide-cel were favorable during the March 15, 2024, FDA ODAC meeting, both BCMA-targeted CAR T-cell therapies received approvals moving them up in the treatment paradigm for relapsed or refractory multiple myeloma.
Read More
Narayan Details How Nadofaragene Firadenovec Has Broken Ground as the First Gene Therapy for NMIBC
April 18th 2024Vikram Narayan, MD, details the mechanism of action of the nadofaragene firadenovec and how the agent is impacting care for patients with BCG-unresponsive non–muscle invasive bladder cancer.
Read More